Patent ID: 8821915

Claim:
A method of treating a patient suffering from a condition selected from the group consisting of metabolic syndrome, obesity, type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and pro-coagulative state, comprising the steps of: (a) providing to said patient suffering from a condition selected from the group consisting of metabolic syndrome, obesity, type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and pro-coagulative state a food product that decreases overactive CNS noradrenergic tone; wherein said food product that decreases overactive CNS noradrenergic tone comprises: 1) protein intake of about 25%±5% of total daily caloric intake; 2) monounsaturated fat intake of about 25%±5% of total daily caloric intake; 3) saturated fat intake of about 5%±5% of total daily caloric intake; 4) polyunsaturated fat intake of about 3%±5% of total daily caloric intake; 5) complex carbohydrate intake of about 42%±7% of total daily caloric intake; and 6) total caloric intake set at 15-25% less than the said patient's daily energy expenditure; followed by (b) providing to said patient a food product that increases dopaminergic tone while maintaining said decreased overactive CNS noradrenergic tone; wherein said food product that increases dopaminergic tone while maintaining said decreased overactive CNS noradrenergic tone comprises: 1) protein intake of about 24%±5% of total daily caloric intake; 2) monounsaturated fat intake of about 23%±5% of total daily caloric intake; 3) saturated fat intake of about 5%±5% of total daily caloric intake; 4) polyunsaturated fat intake of about 3%±5% of total daily caloric intake; 5) complex carbohydrate intake of about 45%±7% of total daily caloric intake; 6) total caloric intake set at 0-25% less than said patient's daily energy expenditure; and 7) L-DOPA-containing foods in an amount sufficient to ingest about 20-400 mg of L-DOPA per day; and wherein said polyunsaturated fat intake in each of steps (a) and (b) individually comprise a ratio of omega-3 to omega-6 polyunsaturated fatty acids from between about 0.25:1 to about 2:1; and wherein said providing step (a) continues for approximately 4 to 12 weeks; and wherein said providing step (b) continues for approximately 4 to 6 months.